Drug Profile
AZD 2461
Alternative Names: AZD2461Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class Antineoplastics
- Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 28 Jul 2011 Discontinued - Phase-I for Solid tumours in USA (PO)
- 23 Nov 2010 Preclinical trials in Solid tumours in USA (PO)